A Phase 1 Study of LY3200882 in Patients With Solid Tumors

Trial Profile

A Phase 1 Study of LY3200882 in Patients With Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs LY 3200882 (Primary) ; Cisplatin; Gemcitabine; LY 3300054; Paclitaxel
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 13 Sep 2017 Planned number of patients changed from 146 to 149.
    • 07 Jul 2017 Planned End Date changed from 1 Sep 2020 to 1 Apr 2020.
    • 07 Jul 2017 Planned primary completion date changed from 1 Mar 2020 to 1 Oct 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top